1-cyclohexylbut-3-en-1-amine | 729597-53-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-cyclohexylbut-3-en-1-amine
• 英文别名: 1-cyclohexylhex-3-en-1-amine
• CAS: 729597-53-9
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: PUQPFCSWXLYFPN-UHFFFAOYSA-N

物化性质

• 沸点：
  218.1±19.0 °C(Predicted)
• 密度：
  0.881±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  吗啉 、 1-cyclohexylbut-3-en-1-amine 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 1,3-双(二苯基膦)丙烷 、 silver(I) 4-methylbenzenesulfonate 作用下， 以 乙二醇二甲醚 为溶剂， 反应 48.0h， 以54%的产率得到1-cyclohexyl-4-morpholinobutan-1-amine
  参考文献：
  名称：

  Anti-Markovnikov Hydroamination of Homoallylic Amines

  摘要：

  The development of an anti-Markovnikov-selective hydroamination of unactivated alkenes is a significant challenge in organometallic chemistry. Herein, we present the rhodium-catalyzed anti-Markovnikov-selective hydroamination of homoallylic amines. The proximal Lewis basic amine serves to promote reactivity and enforce regioselectivity through the formation of the favored metallacycle, thus over-riding the inherent reactivity of the alkene. The scope of both the amine nudeophiles and homoallylic amines that participate in the reaction is demonstrated.

  DOI：

  10.1021/jacs.5b08500
• 作为产物：
  描述：

  环己烷基甲醛 在 copper(II) sulfate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 1-cyclohexylbut-3-en-1-amine
  参考文献：
  名称：

  Anti-Markovnikov Hydroamination of Homoallylic Amines

  摘要：

  The development of an anti-Markovnikov-selective hydroamination of unactivated alkenes is a significant challenge in organometallic chemistry. Herein, we present the rhodium-catalyzed anti-Markovnikov-selective hydroamination of homoallylic amines. The proximal Lewis basic amine serves to promote reactivity and enforce regioselectivity through the formation of the favored metallacycle, thus over-riding the inherent reactivity of the alkene. The scope of both the amine nudeophiles and homoallylic amines that participate in the reaction is demonstrated.

  DOI：

  10.1021/jacs.5b08500

文献信息

• α-Aminoallylation of aldehydes in aqueous ammonia
  作者：Shū Kobayashi、Keiichi Hirano、Masaharu Sugiura

  DOI：10.1039/b415264f

  日期：——

  α-Aminoallylation of aldehydes in aqueous ammonia has been developed; commercial aqueous ammonia was successfully used, and this method does not require anhydrous conditions thus leading to easy and practical operations.

  水合氨中醛的α-氨基烯丙基化方法已得到开发；成功使用了商用水合氨，该方法无需无水条件，从而简化了操作，更具实用价值。
• α-Aminoallylation of Aldehydes with Ammonia:  Stereoselective Synthesis of Homoallylic Primary Amines
  作者：Masaharu Sugiura、Keiichi Hirano、Shū Kobayashi

  DOI：10.1021/ja049689o

  日期：2004.6.1

  Three-component reactions of aldehydes, ammonia, and allylboronates were found to provide homoallylic primary amines in high yields with high chemo- and stereoselectivities. A two-step, one-pot, stereoselective synthesis of an uncommon alpha-amino acid, alloisoleucine, was achieved utilizing this reaction.

  发现醛、氨和烯丙基硼酸酯的三组分反应以高产率和高化学和立体选择性提供均烯丙基伯胺。利用该反应实现了一种不常见的 α-氨基酸别异亮氨酸的两步、一锅、立体选择性合成。
• Addition of Allylmagnesium Bromide to ROPHy/SOPHy Aldoximes: Asymmetric Synthesis of Protected β-Amino Acids
  作者：Christopher J. Moody、James C. A. Hunt

  DOI：10.1055/s-1998-1767

  日期：1998.7

  A new asymmetric synthesis of protected β-amino acids is described in which the key step is the diastereoselective addition of allylmagnesium bromide to O-(1-phenylbutyl) aldoximes.

  描述了一种新的不对称合成保护β-氨基酸的方法，其中关键步骤是烯丙基溴化镁与O-(1-苯基丁基)醛氧肟的立体选择性加成。
• Peptidylaminodiols
  申请人：ABBOTT LABORATORIES

  公开号：EP0189203A2

  公开（公告）日：1986-07-30

  The invention relates to renin inhibiting compounds of the formula: wherein R10 is A is hydrogen or an N-protecting group; w is 0 or 1; B is hydrogen, hydroxy, NH, N-alkyl, loweralkyl or arylalkyl; with the proviso that when w is 1, B is NH and when w is 0, B is hydrogen, hydroxy, loweralkyl or arylalkyl; R1is loweralkyl or lipophilic or aromatic or hydrophilic amino acid side chains; m is 1-3; n is 1-3; p is 1-3; q is 1-3; s is 1-3; t is 0-2; R2 is hydrogen or loweralkyl; R3 and R4 are independently selected from loweralkyl, lipophilic or aromatic amino acid side chains; R5 and R7 are independently selected from hydrogen or loweralkyl; and R6 is hydrogen, loweralkyl, vinyl, arylalkyl or wherein R8 is hydrogen or loweralkyl, X is O, NH or S and R9 is hydrogen, loweralkyl or alkanoyl or XR9 together can be loweralkylsulfonyl, N3 or Cl.

  本发明涉及式中的肾素抑制化合物： 其中 R10 是 A是氢或N-保护基；w是0或1；B是氢、羟基、NH、N-烷基、低级烷基或芳基烷基；但当w是1时，B是NH，当w是0时，B是氢、羟基、低级烷基或芳基烷基；R1是低级烷基或亲油性或芳香性或亲水性氨基酸侧链；m是1-3；n是1-3；p是1-3；q是1-3；s是1-3；t是0-2；R2是氢或低级烷基；R3 和 R4 独立选自低烷基、亲油或芳香族氨基酸侧链；R5 和 R7 独立选自氢或低烷基；R6 是氢、低烷基、乙烯基、芳烷基或其中 R8 是氢或低烷基，X 是 O、NH 或 S，R9 是氢、低烷基或烷酰基或 XR9 合在一起可以是低烷基磺酰基、N3 或 Cl。
• Glaucoma treatment
  申请人：ABBOTT LABORATORIES

  公开号：EP0311012A2

  公开（公告）日：1989-04-12

  A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: wherein A is a substituent; W is CO or CHOH and U is CH₂ or NR₂ wherein R₂ is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is CH₂; R₁ is loweralkyl, cycloalkyl, benzyl, (alpha,­alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino; R₃ is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R₄ is a substituted amino group; or pharmaceutically acceptable salts or esters thereof. Also disclosed are compositions, methods and kits for treating glaucoma or reducing and/or controlling intraocular pressure wherein the renin inhibiting compound is administered in combination with a beta-adrenergic antagonist, a steroidal antiinflammatory agent or an angiotensin converting enzyme inhibiting compound.

  一种治疗或降低和/或控制眼压的方法和组合物，包括施用有效量的式中肾素抑制化合物： 其中 A 是取代基；W 是 CO 或 CHOH，U 是 CH₂ 或 NR₂，其中 R₂ 是氢或低级烷基；但当 W 是 CHOH 时，U 是 CH₂；R₁ 是低级烷基、环烷基、苄基、(α,α)-二甲基苄基、4-羟基苄基、4-甲氧基苄基、卤代苄基、(1-萘基)甲基、(2-萘基)甲基、(4-咪唑酰基)甲基、苯乙基、1-苄氧基乙基、苯氧基、噻吩氧基或苯胺基；R₃ 是低级烷基、低级烯基、（（烷氧基）烷氧基）烷基、羧基烷基、（硫代烷氧基）烷基、苄基或杂环取代的甲基；以及 R₄ 是取代的氨基；或其药学上可接受的盐或酯。 还公开了用于治疗青光眼或降低和/或控制眼压的组合物、方法和试剂盒，其中肾素抑制化合物与β-肾上腺素能拮抗剂、类固醇抗炎剂或血管紧张素转换酶抑制化合物联合给药。